The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of 'superweeds.'» Read More
After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.
Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.
The S&P Biotech ETF is down 7 percent this week. Robyn Karnauskas, Deutsche Bank biotechnology director, shares her large and small cap picks.
CNBC's Meg Tirrell reports biotech stocks are performing lower than the broader markets.
CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.
Quincy College in Massachusetts created a two year program to fill bio-manufacturing technician positions. CNBC's Mary Thompson reports how the school is fueling job growth.
Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.
*Roche adds to breast cancer drug offering with Seragon. Roche is looking to bolster its offering of breast cancer drugs with the purchase. Since walking away from a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012 Roche has eschewed multi-billion deals and instead snapped up a couple of smaller diagnostic companies so far this year.
The biotech ETF soared 67 percent in 2013, but has since been bumpy. Discussing winning and losing stocks in the industry, with Mark Schoenebaum, ISI pharma/biotech analyst.
Emil Kakkis, Ultragenyx founder & CEO, discusses the beginning of its drug KRN23's phase 2 pediatric study to treat 30 kids with bone disorder X-linked hypophosphatemia (XLH).
CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."
CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.
CNBC's Meg Tirell reports Vertex Pharmaceuticals' treatment for cystic fibrosis has succeeded in late stage trials. Vertex will now file applications for U.S. and Europe approval in Q4.
Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.
CNBC's Meg Tirrell reports on everything investors need to know about Vertex Pharmaceuticals' upcoming data release on a combination of drugs for cystic fibrosis.
AstraZeneca has invested $240 million in Moderna Therapeutics to license its technology, which uses messenger RNA therapy to fight cancer.
Medtronic announced that it has agreed to purchase Dublin, Ireland's Covidien for $42.9 billion in cash and stock. CNBC's Meg Tirrell discusses why this deal may be more about taxes than medical devices.
Medtronic bought Covidien for $42.9 billion. Shagun Chadha, CRT Capital Group, discusses what this means for investors and explains the tax savings component of the transaction.
CNBC's Meg Tirrell reports Merck is buying Idenix Pharmaceuticals for $3.85 billion. CNBC contributor Herb Greenberg provides insight on the important deal.